middle.news
Artrya Advances US Launch with $25.18m FY26 Loss and FDA Clearances
11:16am on Wednesday 19th of August, 2026 AEST
•
Healthcare
Read Story
Artrya Advances US Launch with $25.18m FY26 Loss and FDA Clearances
11:16am on Wednesday 19th of August, 2026 AEST
Key Points
FY26 loss after tax increased 53.5% to $25.18m
First US commercial revenues from Salix® platform
FDA clearance for Coronary Plaque module secured
Three US health systems signed long-term contracts
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Artrya (ASX:AYA)
OPEN ARTICLE